Showing results (221-230 of 760) with videos related to
Sort By:
Pageof 76
JACC. Advances|October 28, 2025
Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology PatientsMini K Das, John L Huber, Jamie D Kemp, et al.Cancer Research|September 6, 2005
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cellsMikael Altun, Paul J Galardy, Reshma Shringarpure, et al.Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2013
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cellsDharminder Chauhan, Arghya Ray, Kristina Viktorsson, et al.Oncotarget|November 9, 2017
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.Oncotarget|August 26, 2021
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.Blood|May 14, 2010
Kidney disease associated with plasma cell dyscrasiasEliot C Heher, Nelson B Goes, Thomas R Spitzer, et al.Pageof 76